How Eliquis Reduces Stroke Risk in Atrial Fibrillation
Eliquis (apixaban) cuts stroke and systemic embolism risk by 21% compared to warfarin in patients with non-valvular atrial fibrillation, based on the ARISTOTLE trial. It also lowers major bleeding risk by 31% and clinically relevant non-major bleeding by 34% versus warfarin.[1] Dosing is typically 5 mg twice daily, reduced to 2.5 mg for patients over 80, under 60 kg, or with elevated creatinine.[2]
What the Key Clinical Trials Show
ARISTOTLE enrolled 18,201 patients and tracked outcomes over a median 1.8 years. Annual stroke/embolism rates were 1.27% on Eliquis versus 1.60% on warfarin (HR 0.79, p<0.001). Bleeding rates were 2.13% versus 3.09% (HR 0.69, p<0.001).[1]
The ARISTOTLE subanalysis in East Asians showed even stronger results: stroke/systemic embolism HR 0.28 and major bleeding HR 0.26 versus warfarin.[3] Real-world data from routine care mirrors these, with Eliquis linked to lower stroke and bleeding risks than warfarin or other direct oral anticoagulants.[4]
How Eliquis Stacks Up Against Pradaxa and Xarelto
| Drug | Stroke/Embolism Reduction vs Warfarin | Major Bleeding Reduction vs Warfarin | Key Trial |
|------|---------------------------------------|-------------------------------------|-----------|
| Eliquis (apixaban) | 21% (HR 0.79) | 31% (HR 0.69) | ARISTOTLE[1] |
| Pradaxa (dabigatran) | 34% high-dose (HR 0.66), 9% low-dose (HR 0.91) | 20% high-dose (HR 0.80), increased low-dose | RE-LY[5] |
| Xarelto (rivaroxaban) | 21% (HR 0.79) | No difference (HR 1.03) | ROCKET-AF[6] |
Eliquis edges out on bleeding safety across direct comparisons, though head-to-head stroke efficacy is similar.[7]
Does Eliquis Work for Valvular AF or Other Heart Conditions?
Eliquis is approved only for non-valvular AF (no moderate-severe mitral stenosis or mechanical valves). In valvular AF, warfarin remains standard due to limited data; Eliquis showed higher stroke risk in some subgroups.[8] It's also effective for AF post-ablation or with heart failure, reducing events comparably to warfarin.[9]
Common Patient Concerns: Bleeding Risks and Reversibility
Major bleeding occurs in about 2-4% annually, lower than warfarin but still notable in elderly patients or those on aspirin/NSAIDs. GI bleeds are less common than with Pradaxa.[10] Andexxa (andexanet alfa) reverses Eliquis effects rapidly if needed, unlike warfarin which requires vitamin K.[11]
Who Should Avoid Eliquis?
Contraindicated in active bleeding, severe liver disease, or with strong CYP3A4/P-gp inhibitors like ketoconazole. Renal adjustment needed for CrCl 15-29 mL/min; not recommended below 15.[2] Pregnancy category C—avoid due to fetal risks.
[1]: NEJM - ARISTOTLE Trial
[2]: Eliquis Prescribing Information
[3]: Circulation - ARISTOTLE East Asian Subanalysis
[4]: JAMA - Real-World DOAC Comparison
[5]: NEJM - RE-LY Trial
[6]: NEJM - ROCKET-AF Trial
[7]: Lancet - DOAC Network Meta-Analysis
[8]: FDA Label Updates
[9]: Eur Heart J - AF Post-Ablation
[10]: Gastroenterology - GI Bleeding Meta-Analysis
[11]: NEJM - ANNEXA-4 Trial